Evidence map›Paper›PMID 26176950›Full record

ArticlePloS one2015

Individualized Comprehensive Lifestyle Intervention in Patients Undergoing Chemotherapy with Curative or Palliative Intent: Who Participates?

Karianne Vassbakk-Brovold, Sveinung Berntsen, Liv Fegran, Henrik Lian, Odd Mjåland, Svein Mjåland, Stephen Seiler, Christian Kersten

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Patient preference and timing for exercise in breast cancer care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018
    Article
  5. Dietary Guidelines for Breast Cancer Patients: A Critical Review.Advances in nutrition (Bethesda, Md.) · 2017
    Review
  6. Article
  7. Synergic Effect ofOxidative medicine and cellular longevity · 2016
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Karianne Vassbakk-BrovoldDepartment of Oncology, Southern Hospital Trust, Kristiansand, Norway; Department of Public Health, Sport and Nutrition, Faculty of Health Sport Sciences, University of Agder, Kristiansand, Norway.
Sveinung BerntsenDepartment of Public Health, Sport and Nutrition, Faculty of Health Sport Sciences, University of Agder, Kristiansand, Norway.
Liv FegranDepartment of Health and Nursing Sciences, Faculty of Health and Sport Sciences, University of Agder, Kristiansand, Norway.
Henrik LianDepartment of Physical Medicine and Prevention, Southern Hospital Trust, Kristiansand, Norway.
Odd MjålandDepartment of Surgery, Southern Hospital Trust, Kristiansand, Norway.
Svein MjålandDepartment of Oncology, Southern Hospital Trust, Kristiansand, Norway.
Stephen SeilerDepartment of Public Health, Sport and Nutrition, Faculty of Health Sport Sciences, University of Agder, Kristiansand, Norway.
Christian KerstenDepartment of Oncology, Southern Hospital Trust, Kristiansand, Norway.
Hospital of Southern Norway · NOUniversity of Agder · NO

Funding

Medical Research Council
6 · The paper itself

Abstract

objectiveKnowledge about determinants of participation in lifestyle interventions in cancer patients undergoing chemotherapy, particularly with palliative intent, remains poor. The objective of the present study was to identify determinants of participating in a 12 month individualized, comprehensive lifestyle intervention, focusing on diet, physical activity, mental stress and smoking cessation, in cancer patients receiving chemotherapy with curative or palliative intent. The secondary objective was to identify participation determinants 4 months into the study.

methodsNewly diagnosed cancer patients starting chemotherapy at the cancer center in Kristiansand/Norway (during a 16 month inclusion period) were screened. Demographic and medical data (age, sex, body mass index, education level, marital status, smoking status, Eastern Cooperative Oncology Group performance status (ECOG), diagnosis, tumor stage and treatment intention) was analyzed for screened patients.

results100 of 161 invited patients participated. There were more females (69 vs. 48%; P = 0.004), breast cancer patients (46 vs. 25%; P = 0.007), non-smokers (87 vs. 74%; P = 0.041), younger (mean age 60 vs. 67 yrs; P < 0.001) and fitter (82 vs. 64% with EGOC 0; P = 0.036) participants vs. non-participants included. In multivariate logistic regression analyses, age (Odds Ratio 0.94, 95% Confidence Interval 0.91, 0.97) and smoking (0.42, 0.18, 0.99) were negatively associated with participation. After 4 months, 63 participants were still participating. Cancer type, smoking and age increased the probability of dropping out. Multivariate logistic regression revealed that age was the only significant determinant of 4 month participation (0.95, 0.91, 0.99). Patients aged >70 years were less likely to participate at baseline and 4 months.

conclusionIndividualized lifestyle interventions in cancer patients undergoing chemotherapy appear to facilitate a high participation rate that declines with increasing age; both during the enrollment process and completing the intervention. Neither oncologic nor socioeconomic variables deterred participation.

Indexed as

Palliative CareAgedAntineoplastic AgentsBreast NeoplasmsColorectal NeoplasmsCombined Modality TherapyFemaleHumansLife StyleMaleMiddle AgedPrecision MedicineProstatic NeoplasmsSmoking CessationAntineoplastic Agents

Identifiers

PMID26176950
PMCPMC4503483
OpenAlexW1517775468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.